Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information
MOON SHOTS PROGRAM
Lung cancer develops when cells in the tissues of the lungs grow and multiply uncontrollably. It's the number one cause of cancer deaths worldwide. Treatment of this disease is complicated by its many forms, depending on which particular gene functions incorrectly.
The Lung Cancer Moon Shot® team is revolutionizing the conventional medical research approach to rapidly adapt pre-clinical findings into lung cancer treatment options. We are putting patients at the forefront of our lung cancer investigation to make their cure a reality.
Don Gibbons, M.D., Ph.D.
Associate Professor, Thoracic/Head and Neck Medical Oncology
John Heymach, M.D., Ph.D.
Chair, Thoracic/Head and Neck Medical Oncology
Ara Vaporciyan, M.D.
Chair, Thoracic and Cardiovascular Surgery
“There’s no place where the people doing the research and the people in the clinic treating patients are working together any more closely.”
Moon Shot co-leader John Heymach, M.D., Ph.D., explains what makes the Lung Cancer Moon Shot unique and how your support enables us to bring new treatments to lung cancer patients as quickly as possible.
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Learn moreThe first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
MD Anderson is currently leading a first-of-its-kind study to collect and analyze blood samples from 10,000 heavy smokers in the U.S. This study will enable us to catch lung cancer earlier.
Researchers at MD Anderson have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor regression in mouse models of small cell lung cancer (SCLC), suggesting a promising new approach for treating patients with this aggressive cancer.
A cellular identity switch protects a cancer-promoting genetic
pathway from targeted therapy, researchers at MD Anderson reported.
Working in cell lines and mouse models of lung cancer, a team led by
Don Gibbons, M.D., Ph.D., associate professor of Thoracic/Head and
Neck Medical Oncology, demonstrated how the KRAS-driven lung cancer
cells defeat treatment by switching from stable, stationary cells into
a type of mobile, resistant cell associated with embryonic
development. They also found a drug combination that reversed that
cellular transition and restored vulnerability to targeted
therapy.
